BioWorld

Dec. 14, 2009

Ocrelizumab Hits Endpoint in RA Trial; Safety Questions Remain

Roche subsidiary Genentech Inc. and Biogen Idec Inc. said their first Phase III trial with anti-CD20 antibody ocrelizumab achieved its primary endpoint of improving ACR20 scores in rheumatoid arthritis patients. (BioWorld Today) Read More

Dendreon: $356M Sale to Make Provenge, Gear Up for Launch

Genentech Pact Kaput, SeaGen Revs Effort with Lead Candidate

MiR-206 Affecting Nerve-Muscle Connection to Slow Down ALS

Universal Vaccine: 'End-Game' Pursuit to Counter Flu Pandemic

Other News To Note

Clinic Roundup

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...